RU2009114745A - Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования - Google Patents
Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования Download PDFInfo
- Publication number
- RU2009114745A RU2009114745A RU2009114745/10A RU2009114745A RU2009114745A RU 2009114745 A RU2009114745 A RU 2009114745A RU 2009114745/10 A RU2009114745/10 A RU 2009114745/10A RU 2009114745 A RU2009114745 A RU 2009114745A RU 2009114745 A RU2009114745 A RU 2009114745A
- Authority
- RU
- Russia
- Prior art keywords
- biomarker
- gene expression
- patient
- level
- biological sample
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims abstract 28
- 239000003112 inhibitor Substances 0.000 title claims 5
- 238000000034 method Methods 0.000 claims abstract 39
- 230000014509 gene expression Effects 0.000 claims abstract 26
- 239000012472 biological sample Substances 0.000 claims abstract 13
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims abstract 9
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims abstract 9
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 210000001519 tissue Anatomy 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 230000002062 proliferating effect Effects 0.000 claims abstract 5
- 210000000481 breast Anatomy 0.000 claims abstract 3
- 210000001072 colon Anatomy 0.000 claims abstract 3
- 210000004185 liver Anatomy 0.000 claims abstract 3
- 210000001672 ovary Anatomy 0.000 claims abstract 3
- 210000000496 pancreas Anatomy 0.000 claims abstract 3
- 210000002307 prostate Anatomy 0.000 claims abstract 3
- 210000001685 thyroid gland Anatomy 0.000 claims abstract 3
- 210000003932 urinary bladder Anatomy 0.000 claims abstract 3
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 238000011156 evaluation Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical group N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 claims 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- OMEUGRCNAZNQLN-UHFFFAOYSA-N isis 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- BOJDCYLXQYKJPO-UHFFFAOYSA-N n-[3-[6-[(3-oxo-1h-2-benzofuran-5-yl)amino]pyrazin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=C(NC=3C=C4C(=O)OCC4=CC=3)C=NC=2)=C1 BOJDCYLXQYKJPO-UHFFFAOYSA-N 0.000 claims 1
- GCZVDUHEMXEXOO-UHFFFAOYSA-N n-[5-[[3-(2-cyanopropan-2-yl)benzoyl]amino]-2-methylphenyl]-3-methyl-4-oxoquinazoline-6-carboxamide Chemical compound C1=C(NC(=O)C=2C=C3C(=O)N(C)C=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 GCZVDUHEMXEXOO-UHFFFAOYSA-N 0.000 claims 1
- OIZCAAMXVVUUIZ-UHFFFAOYSA-N n-[5-[[3-(2-cyanopropan-2-yl)benzoyl]amino]-2-methylphenyl]-4-oxo-1h-quinazoline-6-carboxamide Chemical compound C1=C(NC(=O)C=2C=C3C(=O)NC=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 OIZCAAMXVVUUIZ-UHFFFAOYSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84560106P | 2006-09-19 | 2006-09-19 | |
| US60/845,601 | 2006-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009114745A true RU2009114745A (ru) | 2010-10-27 |
Family
ID=39445772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009114745/10A RU2009114745A (ru) | 2006-09-19 | 2007-09-19 | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100004253A1 (enExample) |
| EP (1) | EP2074226A2 (enExample) |
| JP (2) | JP2010504530A (enExample) |
| KR (1) | KR20090071603A (enExample) |
| CN (1) | CN101541977A (enExample) |
| AU (1) | AU2007340265B2 (enExample) |
| BR (1) | BRPI0716944A2 (enExample) |
| CA (1) | CA2662508A1 (enExample) |
| IL (1) | IL197450A0 (enExample) |
| MX (1) | MX2009002936A (enExample) |
| RU (1) | RU2009114745A (enExample) |
| SG (1) | SG174826A1 (enExample) |
| WO (1) | WO2008082730A2 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Inst Inc | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| RU2011102743A (ru) * | 2008-06-26 | 2012-08-10 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| MX2011003183A (es) | 2008-09-26 | 2011-04-21 | Oncomed Pharm Inc | Agentes que se unen a receptor encrespado y usos de los mismos. |
| EP3181705A1 (en) | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
| US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| EP2501236B1 (en) | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US8709419B2 (en) * | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| KR20130113447A (ko) | 2010-09-24 | 2013-10-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화 |
| EP2444503B1 (en) * | 2010-10-20 | 2016-03-02 | Université Joseph Fourier | Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method |
| JP2014500001A (ja) * | 2010-10-21 | 2014-01-09 | オンコセラピー・サイエンス株式会社 | Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| SG194800A1 (en) * | 2011-06-02 | 2013-12-30 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
| BR112013031019A2 (pt) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
| JP2015502958A (ja) * | 2011-12-09 | 2015-01-29 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんの処置のための併用療法 |
| GB2513771B (en) * | 2012-01-09 | 2020-05-27 | Suzhou Microdiag Biomedicine Co Ltd | Biomarkers for breast cancer predictions and diagnoses |
| WO2013148147A1 (en) | 2012-03-26 | 2013-10-03 | The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| KR20240146112A (ko) | 2012-08-17 | 2024-10-07 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| CN105025878A (zh) * | 2012-10-03 | 2015-11-04 | 外来体诊断公司 | 微泡在医学疾病和病况的诊断、预后和治疗中的用途 |
| US11091809B2 (en) | 2012-12-03 | 2021-08-17 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| HK1211887A1 (en) | 2013-02-04 | 2016-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| US10023916B2 (en) * | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
| CN103941016B (zh) * | 2013-05-07 | 2016-04-27 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用 |
| DK2997376T3 (da) * | 2013-05-13 | 2020-09-21 | Roussy Inst Gustave | Prognose og prædiktive biomarkører og biologiske anvendelser deraf |
| US11136625B2 (en) | 2013-08-28 | 2021-10-05 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
| EP3074536B1 (en) * | 2013-11-25 | 2019-06-19 | Children's Hospital Medical Center | Temporal pediatric sepsis biomarker risk model |
| EA201691144A1 (ru) * | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| JP2017500028A (ja) * | 2013-12-12 | 2017-01-05 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗ｄｐｅｐ３抗体および使用方法 |
| EP3090064B1 (en) | 2013-12-31 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| PT3126521T (pt) | 2014-04-04 | 2019-06-27 | Crown Bioscience Inc Taicang | Gene de fusão hnf4g-rspo2 |
| GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
| WO2016011065A1 (en) * | 2014-07-15 | 2016-01-21 | Salk Institute For Biolofical Studies | Detecting dixdc1 (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors |
| US20170242014A1 (en) * | 2014-10-13 | 2017-08-24 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CN104502603B (zh) * | 2014-12-03 | 2016-04-06 | 上海交通大学医学院附属上海儿童医学中心 | Myo1d作为诊断动脉导管闭合或开放的标志物 |
| WO2016131420A1 (zh) | 2015-02-17 | 2016-08-25 | 上海交通大学医学院附属上海儿童医学中心 | 急性淋巴细胞白血病耐药复发相关突变基因及其应用 |
| CN105986023B (zh) * | 2015-02-17 | 2021-01-05 | 上海交通大学医学院附属上海儿童医学中心 | 急性淋巴细胞白血病耐药复发相关突变基因及其应用 |
| WO2016139659A1 (en) | 2015-03-01 | 2016-09-09 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| CN105063183A (zh) * | 2015-07-22 | 2015-11-18 | 浙江理工大学 | 泛素化途径相关基因在作为用于预测乳腺癌新辅助化疗疗效的生物标记物的应用 |
| US20180231565A1 (en) * | 2015-08-09 | 2018-08-16 | Immunarray Ltd | Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes |
| EP3334844A4 (en) * | 2015-08-12 | 2019-11-06 | Celgene Corporation | METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| CN105126080A (zh) * | 2015-09-29 | 2015-12-09 | 武汉大学 | 锌指蛋白436（znf436）在治疗心肌肥厚中的应用 |
| CN105671158B (zh) * | 2016-02-29 | 2019-01-18 | 北京泱深生物信息技术有限公司 | Fam63b基因在制备诊治子宫肌瘤的产品中的用途 |
| MX2018012471A (es) * | 2016-04-15 | 2019-02-21 | Genentech Inc | Metodos de diagnostico y terapeuticos para el cancer. |
| CN105695617A (zh) * | 2016-04-22 | 2016-06-22 | 王冬国 | 乳头状癌的肿瘤标志物及其应用 |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| CN110072526A (zh) * | 2016-08-17 | 2019-07-30 | 西奈山伊坎医学院 | 治疗癌症的激酶抑制剂化合物、组合物和方法 |
| CN108300783A (zh) * | 2017-01-11 | 2018-07-20 | 上海易毕恩基因科技有限公司 | 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途 |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| SG11201907887SA (en) * | 2017-03-15 | 2019-09-27 | Eisai Co Ltd | Spliceosome mutations and uses thereof |
| CN109081866B (zh) * | 2017-06-13 | 2021-07-16 | 北京大学 | 癌症中的t细胞亚群及其特征基因 |
| CN113683698B (zh) * | 2017-06-22 | 2023-03-31 | 北海康成（北京）医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
| AU2018350693B2 (en) | 2017-10-16 | 2021-03-04 | F. Hoffmann-La Roche Ag | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
| CN109825508A (zh) * | 2017-11-23 | 2019-05-31 | 深圳市第三人民医院 | 一种用来评估艾滋病合并结核感染的生物标记物 |
| CN109870576B (zh) * | 2017-12-05 | 2021-08-10 | 中国科学院大连化学物理研究所 | Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用 |
| US12054558B2 (en) * | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| CN108753834B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
| CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
| CN108676867B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | 诊治子痫前期的vwce基因及其应用 |
| CN108624678B (zh) * | 2018-06-26 | 2020-07-17 | 青岛泱深生物医药有限公司 | 一种用于子痫前期诊治的生物标志物 |
| CN108841960B (zh) * | 2018-07-12 | 2022-02-01 | 吉林大学 | 一种结肠腺癌易感性预测试剂盒及系统 |
| CN109468320A (zh) * | 2018-11-13 | 2019-03-15 | 复旦大学附属中山医院 | 一种环状rna及其在肝癌诊断中的应用 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| CN111467493A (zh) * | 2019-01-23 | 2020-07-31 | 首都师范大学 | 人rev3l蛋白切割抑制剂及其应用 |
| CN111896740B (zh) * | 2019-05-06 | 2025-02-11 | 山东大学 | 诊断或预测生育缺陷的试剂盒 |
| EP4039801A4 (en) * | 2019-08-16 | 2023-10-18 | Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences | USE OF PTBP1 INHIBITORS TO PREVENT AND/OR TREAT NERVOUS SYSTEM DISEASES ASSOCIATED WITH FUNCTIONAL NEURONAL DEATH |
| CN110551819B (zh) * | 2019-08-23 | 2023-05-16 | 伯克利南京医学研究有限责任公司 | 一组卵巢癌预后相关基因的应用 |
| CN110408706B (zh) * | 2019-08-30 | 2023-04-11 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种评估鼻咽癌复发的生物标志物及其应用 |
| CN110643571B (zh) * | 2019-10-22 | 2021-07-27 | 康妍葆(北京)干细胞科技有限公司 | 人角蛋白6a在干细胞培养中的应用及产品 |
| KR102261606B1 (ko) * | 2019-11-07 | 2021-06-07 | (주)지노믹트리 | 대장암 검출 방법 |
| CN110819714B (zh) * | 2019-11-22 | 2023-01-10 | 南方医科大学深圳医院 | 一种抑癌基因及其应用 |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| CN116194121A (zh) * | 2020-06-09 | 2023-05-30 | 吉尼松公司 | 用于治疗扩张型心肌病的cilp-1抑制剂 |
| CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
| CN113943798B (zh) * | 2020-07-16 | 2023-10-27 | 中国农业大学 | 一种circ RNA作为肝细胞癌诊断标志物及治疗靶点的应用 |
| CN112816708B (zh) * | 2021-02-02 | 2022-05-31 | 中南大学湘雅二医院 | 一种预测食管鳞癌患者对化疗药物敏感性的蛋白指标及应用 |
| CN112691195B (zh) * | 2021-02-02 | 2023-03-14 | 黑龙江省科学院高技术研究院 | Prpf8表达抑制剂在制备治疗肺癌的药物中的应用 |
| CN112816711B (zh) * | 2021-03-17 | 2024-04-19 | 中国医科大学附属盛京医院 | 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用 |
| CN113373220A (zh) * | 2021-05-08 | 2021-09-10 | 首都医科大学 | 与非小细胞肺癌预后相关的标志分子 |
| CN113416739B (zh) * | 2021-06-24 | 2022-04-19 | 黑龙江八一农垦大学 | 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用 |
| CN113667749A (zh) * | 2021-08-03 | 2021-11-19 | 广东省人民医院 | 四个关键基因组合评估乳腺癌风险的诊断试剂盒 |
| CN113866424A (zh) * | 2021-09-14 | 2021-12-31 | 哈尔滨医科大学 | 碳酸酐酶1和酸性鞘磷脂酶样磷酸二酯酶3a作为分子标志物在结直肠癌诊断中的应用 |
| CN113897437B (zh) * | 2021-11-30 | 2024-06-04 | 深圳市人民医院 | 检测样本中标志物表达水平的试剂在制备用于诊断乳腺癌的试剂盒中的应用 |
| CN114592059A (zh) * | 2022-01-11 | 2022-06-07 | 南方医科大学南方医院 | 一种评估5-fu治疗敏感性/耐药性的试剂盒 |
| CN114525342B (zh) * | 2022-03-03 | 2025-02-14 | 温州医科大学附属第一医院 | Linc02806在肝细胞癌诊断和治疗中的应用 |
| CA3246050A1 (en) * | 2022-03-16 | 2025-02-04 | Shanghai Shijiang Biotechnology Co Ltd | Nitrogen-containing heterocyclic compound and use thereof |
| CN114672551B (zh) * | 2022-05-17 | 2023-03-31 | 中国医科大学附属第一医院 | Mat2a和mat2b作为检测或治疗良性前列腺增生的药物靶点的应用 |
| CN115389764A (zh) * | 2022-07-28 | 2022-11-25 | 宁波大学 | 蛋白质fbxo7在制备子宫内膜癌诊断标志物中的应用 |
| CN115948529A (zh) * | 2022-08-01 | 2023-04-11 | 湖南家辉生物技术有限公司 | 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用 |
| CN116179691A (zh) * | 2022-09-07 | 2023-05-30 | 苏州大学附属第一医院 | 一种胃癌组合标志物及标志物模型的建立方法 |
| WO2024107924A2 (en) * | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | A blood-based lipid biomarker panel for personalized risk assessment of breast cancer |
| CN115948537B (zh) * | 2022-12-19 | 2024-04-09 | 湖南家辉生物技术有限公司 | 一种基因chst3复合杂合突变的应用及检测试剂和应用 |
| CN116287253B (zh) * | 2023-02-22 | 2024-06-28 | 武汉科技大学 | 一种肺癌分子标志物及其应用 |
| CN116430048B (zh) * | 2023-03-07 | 2025-06-20 | 南通大学附属医院 | BTF3L4基因及其RNAi干扰系统的应用 |
| CN116500266B (zh) * | 2023-03-07 | 2025-06-17 | 南通大学附属医院 | MRPS21基因及其RNAi干扰系统的应用 |
| CN117100866B (zh) * | 2023-03-31 | 2025-10-28 | 兰州大学第二医院 | 一种抗肿瘤血管生成药物增效剂、抗肿瘤药物组合物及应用 |
| CN116769916B (zh) * | 2023-06-27 | 2025-03-07 | 南通大学附属医院 | Tmed8基因在制备胰腺癌药物及其诊断试剂盒中的应用 |
| CN116747215A (zh) * | 2023-07-14 | 2023-09-15 | 新疆医科大学第三附属医院 | V-9302在抑制肝癌和增强索拉菲尼抑癌作用中的应用 |
| CN117257919B (zh) * | 2023-11-10 | 2024-10-01 | 南通大学附属医院 | Tbc1d15在筛选或制备保护肝脏的药物中的应用 |
| CN117821469B (zh) * | 2023-11-22 | 2024-08-02 | 扬州大学 | 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用 |
| CN118045083B (zh) * | 2024-04-15 | 2024-06-18 | 哈尔滨医科大学 | L-脯氨酸在制备防治非酒精性脂肪肝病药物中的新用途 |
| CN118879858B (zh) * | 2024-06-27 | 2025-09-30 | 中国科学院合肥物质科学研究院 | 一组用于预测非小细胞肺癌放疗预后的基因标签及应用 |
| CN120442707B (zh) * | 2025-07-14 | 2025-09-09 | 三亚中国农业科学院国家南繁研究院 | 棉花耐旱性和耐低温性相关蛋白GhCOX11及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| US20030119769A1 (en) * | 1994-05-31 | 2003-06-26 | Monia Brett P | Antisense oligonucleotide modulation of raf gene expression |
| US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) * | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| CA2256109A1 (en) * | 1996-05-23 | 1997-11-27 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US7351834B1 (en) * | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6610484B1 (en) * | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
| US20040018570A1 (en) * | 1999-09-01 | 2004-01-29 | Brown University | Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth |
| AU2003222221A1 (en) * | 2002-02-15 | 2004-10-25 | The General Hospital Corporation | Map-kinase inhibitors as regulators of tumour-associated antigen expression |
| US20040224302A1 (en) * | 2002-07-16 | 2004-11-11 | Thomas Jessel | Systems and methods for screening for modulators of neural differentiation |
| CA2499852A1 (en) * | 2002-09-30 | 2004-04-08 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| US8053183B2 (en) * | 2005-07-27 | 2011-11-08 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
-
2007
- 2007-09-19 RU RU2009114745/10A patent/RU2009114745A/ru not_active Application Discontinuation
- 2007-09-19 MX MX2009002936A patent/MX2009002936A/es active IP Right Grant
- 2007-09-19 CN CNA2007800426892A patent/CN101541977A/zh active Pending
- 2007-09-19 WO PCT/US2007/078946 patent/WO2008082730A2/en not_active Ceased
- 2007-09-19 KR KR1020097007973A patent/KR20090071603A/ko not_active Ceased
- 2007-09-19 SG SG2011067519A patent/SG174826A1/en unknown
- 2007-09-19 BR BRPI0716944-2A2A patent/BRPI0716944A2/pt not_active IP Right Cessation
- 2007-09-19 JP JP2009529376A patent/JP2010504530A/ja active Pending
- 2007-09-19 AU AU2007340265A patent/AU2007340265B2/en not_active Ceased
- 2007-09-19 EP EP07872305A patent/EP2074226A2/en not_active Withdrawn
- 2007-09-19 US US12/441,888 patent/US20100004253A1/en not_active Abandoned
- 2007-09-19 CA CA002662508A patent/CA2662508A1/en not_active Abandoned
-
2009
- 2009-03-05 IL IL197450A patent/IL197450A0/en unknown
-
2013
- 2013-01-30 JP JP2013015294A patent/JP2013128487A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007340265B2 (en) | 2012-07-26 |
| MX2009002936A (es) | 2009-04-01 |
| BRPI0716944A2 (pt) | 2013-09-17 |
| SG174826A1 (en) | 2011-10-28 |
| AU2007340265A1 (en) | 2008-07-10 |
| CN101541977A (zh) | 2009-09-23 |
| KR20090071603A (ko) | 2009-07-01 |
| CA2662508A1 (en) | 2008-07-10 |
| US20100004253A1 (en) | 2010-01-07 |
| WO2008082730A2 (en) | 2008-07-10 |
| WO2008082730A3 (en) | 2009-01-08 |
| JP2010504530A (ja) | 2010-02-12 |
| IL197450A0 (en) | 2009-12-24 |
| JP2013128487A (ja) | 2013-07-04 |
| EP2074226A2 (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009114745A (ru) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования | |
| Öberg et al. | A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood | |
| Adler et al. | Metastatic pathways in patients with cutaneous melanoma | |
| Field et al. | Recent developments in prognostic and predictive testing in uveal melanoma | |
| Gupta et al. | Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification | |
| US20130178393A1 (en) | Methods and kits for the diagnosis of prostate cancer | |
| RU2012111231A (ru) | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK | |
| Dong et al. | Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage i–iii non-small cell lung cancer patients | |
| Choi et al. | Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses | |
| Zablocka et al. | Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma | |
| Pearl et al. | Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy | |
| Sharma et al. | Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study | |
| JP7633159B2 (ja) | メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー | |
| Wilson | Histopathologic and molecular diagnosis of melanoma | |
| Aktas et al. | Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow | |
| Chen et al. | Measurable residual disease (MRD)-testing in haematological and solid cancers | |
| Morinaga et al. | Glasgow prognostic score predicts clinical outcomes in patients with pancreatic cancer undergoing adjuvant gemcitabine monotherapy after curative surgery | |
| Rynda et al. | Patients with long-term survival in malignant gliomas after photodynamic therapy | |
| Reiher et al. | p53 and microvessel density in primary resection specimens of superficial bladder cancer | |
| RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
| Gee et al. | Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| Lei et al. | The combined use of fine-needle aspiration (FNA) and BRAF V600E gene testing: can it increase the definitive diagnosis rate of nodules categorized as Bethesda III for papillary thyroid carcinoma? | |
| Le et al. | CXCL5 expression is associated with active signals of macrophages in the microenvironment of papillary thyroid carcinoma | |
| Ji et al. | Molecular profiling in cutaneous melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20140707 |